UNION Therapeutics
@uniontherapeutics.com
UNION therapeutics is a privately held, clinical stage, pharmaceutical development company advancing novel treatment options within immunology, a large and fast-growing therapeutic area. UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs.
UNION Therapeutics's Company Logos
UNION Therapeutics's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#7490C0
Ship Cove
116, 144, 192
218, 38, 60
40, 25, 0, 25
#9896F0
Portage
152, 150, 240
241, 75, 76
37, 37, 0, 6
#000000
Black
0, 0, 0
0, 0, 0
0, 0, 0, 100
About UNION Therapeutics
UNION Therapeutics is a clinical-stage pharmaceutical development company based in Greater Copenhagen, Denmark. They are dedicated to identifying, developing, and commercializing treatments for immunology and infectious diseases. With a focus on addressing unmet medical needs, UNION's current portfolio consists of medicinal compounds with established modes of action that hold significant potential.
Led by an international team of biotech entrepreneurs and seasoned pharma executives, UNION follows a scalable and capital-efficient business model. They prioritize the identification and development of well-characterized molecules with broadly applicable modes of action and demonstrated safety within immunology and infectious diseases. This approach allows them to maintain a clinical-stage pipeline with shorter time to market and capitalize on multiple growth opportunities.
One of UNION's promising developments is orismilast, a high-potency next-generation PDE4 inhibitor. With broad anti-inflammatory properties and an attractive therapeutic window, orismilast has the potential to be a first-in-class and best-in-class treatment for immunology
Company type
Privately Held
Year founded
2011
Company size
11-50 employees
